★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Stryker Corporation (SYK) Moat Analysis
Stryker Corporation
SYK · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Stryker reports MedSurg and Neurotechnology plus Orthopaedics. Q2 2026 mix was 55.02% and 44.98% of sales, and the segments supplied 50.27% and 49.73% of segment operating income, respectively. MedSurg retains moderate field-network and clinical-brand advantages; Orthopaedics retains strong surgeon/OR workflow switching costs around instruments and Mako plus a moderate service-network barrier. Generic patent language does not establish a product-specific IP choke point and is no longer scored. Recalculated June 2026 TTM margins are 64.98% gross, 21.42% operating and 14.43% net; the quarter included a $158m reversal of 2025 tariffs. At June 30, 2026, 383,573,046 single-class common shares were outstanding; SYK is ordinary U.S. common stock on NYSE, not an ADR. The CIK, active/issued LEI, CUSIP and ISIN were reconciled, and both security identifiers pass check digits.
Primary segment
MedSurg and Neurotechnology
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
2 segments · 7 tags
Updated 2026-08-23
Segments
MedSurg and Neurotechnology
Hospital medical devices: surgical equipment and navigation, endoscopy and visualization, patient handling and emergency care, neurosurgical and neurovascular devices
Revenue
55%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Orthopaedics
Orthopaedic implants and enabling technologies (joint replacement, trauma and extremities; includes surgical robotics such as Mako)
Revenue
45%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
MedSurg and Neurotechnology
Hospital medical devices: surgical equipment and navigation, endoscopy and visualization, patient handling and emergency care, neurosurgical and neurovascular devices
Revenue_share uses Q2 2026 net sales of $3.625bn over $6.589bn consolidated sales. Operating_profit_share uses $1.019bn of segment operating income over $2.027bn total segment operating income; unallocated items are excluded from the denominator.
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
A broad, specialized field organization supports procedure-adjacent selling and service across many hospital product lines. Q2 segment sales grew 9.7% with a 28.1% operating margin, but large medtech peers maintain comparable networks.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Hospital consolidation and GPOs reduce rep influence
- Competitors match service levels and bundle offerings
- Remote support and teleproctoring reduce need for in-person presence
Leading indicators
- SG&A as % of sales
- New product launch cadence and uptake
- Field service response times
Counterarguments
- Large medtech peers also maintain extensive sales forces
- Purchasing decisions can shift to centralized procurement despite clinical preference
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Clinical reputation for innovation, quality and service supports adoption across MedSurg and Neurotechnology, but the portfolio spans many categories and the filing does not quantify a brand premium.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Product recalls or safety issues damage trust
- Clinical outcomes parity reduces differentiation
- Fast-moving AI and robotics feature parity compresses premium
Leading indicators
- Recall and field action frequency and severity
- Independent clinical evidence quality and volume
- Gross margin and price/mix trends
Counterarguments
- Hospitals may prioritize total cost over brand in commoditized subcategories
- Reputation advantages can erode quickly after adverse events
Orthopaedics
Orthopaedic implants and enabling technologies (joint replacement, trauma and extremities; includes surgical robotics such as Mako)
Revenue_share uses Q2 2026 net sales of $2.964bn over $6.589bn consolidated sales. Operating_profit_share uses $1.008bn of segment operating income over $2.027bn total segment operating income. Spinal Implants contributed only $3m after the divestiture.
Training Org Change Costs
Demand
Training Org Change Costs
Strength
Durability
Confidence
Evidence
Specialized instrumentation and Mako workflows embed Stryker into surgeon technique, capital planning and operating-room processes. More than one million robotic knees and a 34.0% Q2 segment margin support demonstrated scale and economics.
Training Org Change Costs moat: definition, examples, and stocks
Erosion risks
- Competing robotics platforms win new placements
- Hospitals standardize implants via bundled procurement
- Surgeon mobility and multi-system training lowers lock-in
Leading indicators
- Mako robotic procedure volume growth
- Robot placements and utilization per robot
- Share shifts in knees and hips categories
Counterarguments
- Robotics differentiation can narrow as peers scale competing systems
- Switching can occur at contract renewal or technology refresh cycles
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Procedure-adjacent support, instrument logistics and training require dense field coverage. This complements workflow switching costs but is scored separately as a route-to-market barrier; leading orthopaedic peers can replicate it.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Centralized purchasing reduces importance of in-room support
- Competitors replicate service models and logistics
- Staffing constraints in reps and clinical specialists
Leading indicators
- Salesforce productivity
- Instrument set availability and turn times
- Customer satisfaction and contract renewals
Counterarguments
- Top peers also have deep field organizations
- Service advantages may not overcome price pressure in commoditized implants
Evidence
The competitive environment requires substantial investments in continuing research and maintaining sales forces.
Management explicitly frames sustained investment in sales forces as a competitive requirement.
...our commitment to innovation, quality and service and our reputation differentiates us...
Direct statement that reputation, quality, and service differentiates Stryker in highly competitive product categories.
...advanced implant designs and specialized instrumentation... We support surgeons with the technologies, products and services...
Supports that Orthopaedics relies on specialized instrumentation and surgeon-facing services that require adoption and integration.
...Mako SmartRobotics ... sold in more than 45 countries... more than one million robotic Mako Total Knees...
Large procedure history and geographic footprint suggest deep workflow embedment and trained user base.
...requires substantial investments... maintaining sales forces.
Supports that sustained sales force investment is a competitive necessity across product lines, especially in procedure-driven categories like Orthopaedics.
Risks & Indicators
Erosion risks
- Hospital consolidation and GPOs reduce rep influence
- Competitors match service levels and bundle offerings
- Remote support and teleproctoring reduce need for in-person presence
- Product recalls or safety issues damage trust
- Clinical outcomes parity reduces differentiation
- Fast-moving AI and robotics feature parity compresses premium
Leading indicators
- SG&A as % of sales
- New product launch cadence and uptake
- Field service response times
- Recall and field action frequency and severity
- Independent clinical evidence quality and volume
- Gross margin and price/mix trends
Research SYK elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.